BPC-157 — Body Protection Compound-157 — is a synthetic 15-amino acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein isolated from human gastric juice. First described by researchers studying the gastroprotective factors present in the gastrointestinal mucosa, BPC-157 has since been investigated across a broad range of tissue types for its potential to accelerate healing, modulate vascular growth, and protect cells under stress conditions. Its stable structure in physiological environments makes it a reproducible and extensively studied research compound.
What Is BPC-157?
BPC-157 is a partial sequence of the larger Body Protection Compound protein found naturally in gastric juice. Unlike many endogenous peptides, BPC-157 demonstrates notable stability in the presence of gastric acid, making it a resilient candidate for both systemic and local research applications. Researchers have studied it in numerous in vitro and in vivo models — including rodent, rabbit, and canine models — to characterise its effects on tissue of diverse origin. Its designation as a "pentadecapeptide" refers specifically to its 15-amino acid composition.
Mechanisms of Action
Angiogenesis and VEGF Upregulation
One of the most consistently observed properties of BPC-157 in preclinical research is its capacity to stimulate angiogenesis — the formation of new blood vessels from existing vasculature. Studies suggest BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) signalling and promotes endothelial cell migration. Enhanced vascularisation at injury sites accelerates the delivery of nutrients and immune cells necessary for tissue regeneration, and this effect has been observed in musculoskeletal, gastrointestinal, and dermal repair models.
Collagen Synthesis and Fibroblast Activity
BPC-157 has been shown to stimulate fibroblast proliferation and collagen synthesis in research models. Fibroblasts are the primary producers of collagen — the structural protein essential for connective tissue integrity. Research examining tendon and ligament repair has documented increased expression of collagen type I and improved structural organisation of repaired tissue in subjects administered BPC-157 compared to controls. This mechanism is of particular interest in musculoskeletal injury research.
Nitric Oxide Modulation
The nitric oxide (NO) pathway appears to be a significant mediator of BPC-157's cytoprotective effects. In gastrointestinal research, BPC-157 has been shown to preserve nitric oxide synthase (NOS) activity in gastric mucosa under conditions of chemical or stress-induced injury. Nitric oxide plays a critical role in mucosal blood flow, epithelial cell survival, and inflammatory regulation — functions central to the gastrointestinal protection observed in BPC-157 studies.
Growth Factor and Receptor Modulation
Research has identified interactions between BPC-157 and several growth factor pathways, including epidermal growth factor (EGF) receptor signalling and fibroblast growth factor (FGF) activity. These interactions appear to contribute to BPC-157's ability to enhance cellular proliferation and differentiation at injury sites, broadening its potential applications across tissue types.
Research Applications
Musculoskeletal Repair
Animal models of muscle tear, tendon transection, and ligament damage have been used to evaluate BPC-157's regenerative potential. Studies have consistently reported accelerated healing timelines, improved tensile strength of repaired tissue, and reduced histological damage scores in BPC-157-treated subjects. Tendon-to-bone healing, in particular, has been an active area of investigation given the clinical challenges associated with this tissue interface in orthopaedic research.
Gastrointestinal Protection
Given its origin in gastric juice, BPC-157 has been extensively studied in models of gastrointestinal injury. Research subjects with experimentally induced gastric ulcers, NSAID-associated mucosal damage, and inflammatory bowel conditions have demonstrated significant reductions in ulcer size, mucosal inflammation markers, and histological damage following BPC-157 administration. The peptide has also been explored in models of intestinal anastomosis — surgical bowel reconnection — where improved healing integrity has been reported.
Systemic Anti-Inflammatory Effects
BPC-157 research has shown reductions in pro-inflammatory cytokine profiles in models of systemic inflammation, including those involving experimental sepsis and organ injury. These findings have prompted interest in BPC-157 as a model compound for studying how locally derived gastric peptides may exert systemic anti-inflammatory effects via circulatory and neural pathways.
Conclusion
BPC-157 represents one of the most extensively researched peptides in preclinical regenerative science. Its multi-faceted mechanisms — spanning angiogenesis, collagen production, nitric oxide modulation, and growth factor regulation — make it a valuable tool for investigating tissue repair across multiple organ systems. The depth of existing research positions BPC-157 as a foundational compound for investigators studying regenerative biology, gastrointestinal physiology, and connective tissue repair. For a side-by-side comparison of BPC-157 and TB-500 across specific research endpoints, see our detailed BPC-157 vs TB-500 comparison. Malaysian researchers focused on joint repair models can find additional context in our guide to peptides for joint pain Malaysia, and sourcing information is available in our guide on how to buy BPC-157 Malaysia.
References
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Current Medicinal Chemistry. 2012;19(1):126–132.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774–780.
- Tkalcevic VI, Cuzic S, Brajsa K, et al. "Enhancement by PL 14736 of granulation and collagen organisation in healing wounds." European Journal of Pharmacology. 2007;570(1–3):212–221.
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612–1632.